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Abstract
Background: Germ cell testicular tumors have survival rate that diminishes with high tumor marker
levels, such as human chorionic gonadotropin (hCG). hCG may regulate vascular neoformation through
vascular endothelial growth factor (VEGF). Our purpose was to determine the relationship between hCG
serum levels, angiogenesis, and VEGF expression in germ cell testicular tumors.
Methods: We conducted a retrospective study of 101 patients. Serum levels of hCG, alpha-fetoprotein
(AFP), and lactate dehydrogenase were measured prior to surgery. Vascular density (VD) and VEGF tissue
expression were determined by immunohistochemistry and underwent double-blind analysis.
Results: Histologically, 46% were seminomas and 54%, non-seminomas. Median follow-up was 43 ± 27
months. Relapse was present in 7.5% and mortality in 11.5%. Factors associated with high VD included
non-seminoma type (p = 0.016), AFP ≥ 14.7 ng/mL (p = 0.0001), and hCG ≥ 25 mIU/mL (p = 0.0001). In
multivariate analysis, the only significant VD-associated factor was hCG level (p = 0.04). When hCG levels
were stratified, concentrations ≥ 25 mIU/mL were related with increased neovascularization (p < 0.0001).
VEGF expression was not associated with VD or hCG serum levels.
Conclusion: This is the first study that relates increased serum hCG levels with vascularization in
testicular germ cell tumors. Hence, its expression might play a role in tumor angiogenesis, independent of
VEGF expression, and may explain its association with poor prognosis. hCG might represent a molecular
target for therapy.
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Background
Testicular cancer is a clinically, epidemiologically, and
histologically heterogeneous group of neoplasms that
represents 1% of malignant tumors in males. Germ cell
testicular cancer is the most common type of tumor in
males between 15 and 40 years of age, comprising approx-
imately 98% of all testicular cancers, with an annual inci-
dence of 7.5 per 100,000 inhabitants [1-3]. Germ cell
testicular tumors are classified into two major sub-groups
based on histological findings: seminomas and non-sem-
inomas, each comprising approximately 50% of cases.
This malignancy possesses a high cure rate in its early and
even in its metastatic stages, reaching 10-year survival
rates between 90 and 100% [4,5]. However, there remains
a sub-group of patients with poor prognosis with approx-
imately 40% of 10-year mortality, regardless of treatment.
In addition, 20–30% of germ cell tumors show recurrence
that frequently exhibits refractoriness to multi-agent
chemotherapy.
Human chorionic gonadotropin (hCG), alpha-fetopro-
tein (AFP), and lactate dehydrogenase (LDH) are serum
tumor markers (STMs) that play a clear role in diagnosis,
staging, risk classification, and clinical management of
testicular germ cell tumors. Elevation of one or more
markers is associated with disease progression and
adverse prognosis [6,7]. Seminoma tumors do not
increase AFP levels, and occasionally increase hCG [8].
One main feature of cancer is marked angiogenesis, which
is essential for tumor growth and metastasis, exerting an
impact on outcome and survival rates, including those of
germ cell testicular tumors. The most important ang-
iogenic stimulatory factor is vascular endothelial growth
factor (VEGF), a mitogen specific for vascular endothelial
cells [9]. VEGF is known for its ability to induce vascular
permeability, to promote endothelial proliferation as well
as migration, and to act as a critical survival factor for
endothelial cells [10]. VEGF mRNA and protein expres-
sion is significantly higher in germ cell testicular tumors
than in normal testis, and this expression correlates with
microvascular density within the tumor [11]. Moreover, it
has been shown that VEGF expression is correlated with
metastases in these tumors [12].
hCG is a well-characterized hormone primarily produced
by placenta and by other normal and tumor tissues in
small amounts [13]. It has been described not only as an
important peptide hormone during implantation [14],
but also as an angiogenic factor for uterine endothelial
cells [15]. It has been found that hCG possesses a role in
the angiogenic process in vivo and in vitro by increasing
capillary formation and endothelial cell migration in a
direct association with the quantity of hCG administered;
also, hCG-induced neovascularization was similar to that
produced by VEGF and basic fibroblastic growth factor
(bFGF) [16]. In addition, it has been proposed that hCG
could induce VEGF production in tissues such as placenta
[17] and granulosa cells [18,19].
Elevated hCG expression in serum, urine, or tumor tissue
is usually a sign of aggressive disease and poor prognosis
in germ cell tumors [8]. It is found in 40–60% of non-
seminomatous germ cell tumors and in 30% of seminoma
germ cell tumors [20]. However, no direct association has
been reported between hCG and angiogenesis in cancer.
The objective of this study was to determine the relation-
ship between hCG serum levels, angiogenesis, and VEGF
expression in germ cell testicular tumors.
Methods
Experimental design and patients
With previous Institutional Research and Ethics Board
approval, we conducted a retrospective analytical study at
the Instituto Nacional de Cancerología in Mexico City. We
studied the tumor tissue of 101 patients with a diagnosis
of germ cell testicular cancer that underwent surgery
between 1992 and 2002.
AFP (normal range: 0–8.5 ng/mL), hCG (normal range:
0–4 mIU/mL), and LDH (normal range: 119–213 UI/L)
serum levels were performed in all patients prior to sur-
gery and before receiving chemotherapy, for risk stratifica-
tion and follow-up. These markers were determined by
using routine automated analyzers in the Department of
Clinical Chemistry and Serum Markers, Instituto
Nacional de Cancerología. The hCG was measured using
the SIEMENS IMMULITE 2000 which is a highly specific,
solid-phase, two-site chemiluminiscent immunometric
assay that measures intact hCG without nicked forms and
free subunits (Siemens; Los Angeles, CA, USA). AFP was
measured with SIEMENS IMMULITE 2000 (Siemens; Los
Angeles, CA, USA) and LDH with SYNCHRON LX20
(Beckman Coulter; Fullerton, CA, USA). Abdominal com-
puted tomography scan and conventional chest x-ray were
performed for disease staging according to the AJCC sys-
tem. A database was made containing the clinical varia-
bles of all patients including IGCCCG risk status
classification. Patients who received chemotherapy, radio-
therapy, or both previous to surgery were excluded.
Tissue retrieval and immunohistochemistry assays
Initial diagnostic biopsies were fixed in 10% neutral buff-
ered formalin and embedded in paraffin. Morphologic
evaluation was made in 3-μm tissue sections stained by
the standard hematoxylin-eosin method. Sections 3-μm
in thickness were mounted on slides and subsequently
deparaffinized and rehydrated. Antigen was retrieved with
10 mM sodium citrate solution (pH 6.0) preheated toJournal of Experimental & Clinical Cancer Research 2009, 28:120 http://www.jeccr.com/content/28/1/120
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80°C, maintaining this temperature and keeping sections
in this solution for 10 min in a microwave pressure
cooker. After allowing the sections to cool to room tem-
perature, the slides were rinsed in PBS (pH 7.4). Endog-
enous peroxidase activity was blocked by incubation of
the tissue samples for 10 min in 3% hydrogen peroxide.
Samples were incubated for 45 min with the primary anti-
bodies at room temperature in a moisture chamber.
VEGF determination and analysis
Samples were incubated with mouse anti-VEGF mono-
clonal antibody (1:100) (Abcam, Cambridge MA, USA) in
BSA 1% in PBS for 45 min. After washing with PBS, bind-
ing of the primary antibodies was revealed by incubation
for 20 min with LSAB+ System Link (DAKO, Carpinteria,
CA, USA) and LSAB+ HRP, (Streptavidin HRP kit, DAKO).
The slides were rinsed with PBS and exposed to diami-
nobenzidine for 5 min. After washing with PBS and coun-
ter-staining with hematoxylin, the slides were dehydrated
by graduated alcohols and xylol, and mounted with Poly-
mount. Numerical proportions of stained cells were estab-
lished by analyzing 10 high-power fields (400×) in each
section. Only cytoplasmic staining was considered posi-
tive. Intensity was graded on a semi-quantitative scale
from 0–3. Graduation of expression was considered nega-
tive if fewer than 5% of cells were stained.
Determination of vascular density
The samples were incubated for 45 min with mouse anti-
CD34 monoclonal antibody (1:200) (Biocare Medical,
Concord, CA, USA) as a marker for vascular endothelial
cells. Three separated, highly vascularized areas ("hot
spots"), previously identified in high-power fields (100×,
then 400×), were analyzed by two pathologists by means
of optic microscopy without previous knowledge of hCG
determinations. Any immunostained vessel clearly sepa-
rated from adjacent vessels with no muscular wall and
within the optic field was considered a neovascularization
vessel. Vascular density (VD) was considered as the aver-
age of the three evaluated zones.
Statistical analysis
For descriptive purposes, continuous variables were sum-
marized as arithmetic means, medians, and standard devi-
ations (SDs), while categorical variables were expressed as
proportions and confidence intervals (CIs). Inferential
comparisons were carried out using the Student t or the
Mann-Whitney  U  test, according to data distribution
determined by the Kolmogorov-Smirnov test. Chi square
or Fisher exact test was used to assess significance between
categorical variables. Statistically significant and border-
line-significant variables (p < 0.1) were included in the
multivariate logistic regression analysis. Overall survival
time was measured from day of surgery to date of death or
last follow-up visit and analyzed with the Kaplan-Meier
method, and comparisons among sub-groups were per-
formed with the log-rank test. For survival curve analysis,
all variables were dichotomized. Adjustment for potential
confounders was performed by multivariate regression
analysis. Statistical significance was determined as p  <
0.05 with a two-sided test. SPSS software package version
16 (SPSS Inc., Chicago, IL, USA) was employed to analyze
the data.
Results
A total of 109 patients were included. Two patients were
excluded due to insufficient biopsy material and six
because a different method to measure hCG was used.
General patient characteristics are shown in Table 1. From
a total of 101 tumors, non-seminomas corresponded to
54%, and seminomas to 46%. Diagnosis was confirmed
by the pathologists, independent of the general character-
istics of the patients. The most frequent histological sub-
types were endodermal sinus tumors and mature ter-
atoma in 21.8 and 14.9% of cases, respectively. Median
age was 26 ± 7.7 years. The majority of patients (70.7%)
had good risk according to the international risk
(IGCCCG). hCG median and mean serum levels were
25.0 (range, 0–479000) and 14772 ± 71503, respectively.
Only 10% of patients had hCG levels >5,000 mIU/mL, as
shown in Table 2, percentiles for hCG, AFP and DHL val-
ues are also stated in this table.
Table 1: Patient characteristics (101 patients)
Characteristic % Median ± SD
Age (years) 26 ± 7.7
Histology
Seminoma 46
Non-seminoma 54
Endodermal sinus 21.8
Choriocarcinoma 5.0
Embryonal cell carcinoma 8.9
Mature teratoma 14.9
Immature teratoma 2.0
Teratocarcinoma 1.0
TNM stage
I4 6 . 5
II 27.3
III 26.3
Metastasis (N or M)
Absent 48.5
Present 51.5
International consensus risk
Good 70.7
Intermediate 16.2
Poor 13.1
SD = standard deviation; TNM = Tumor, Node, MetastasisJournal of Experimental & Clinical Cancer Research 2009, 28:120 http://www.jeccr.com/content/28/1/120
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Vascular density (VD) was determined in all samples.
Median VD was 19.0 ± 28.9 (95% Confidence interval
[95% CI], 5–75). Factors associated with higher VD were
the following: AFP serum levels >14.7 ng/mL (p  =
0.0001); serum hCG levels ≥ 25 mIU/mL (p = 0.0001),
and non-seminomatous histologic type (p = 0.016) (Table
3 and 4). However, the sole factor independently related
with VD was hCG elevation above the median (p = 0.04)
(Table 5). When hCG levels were divided as <25 and ≥ 25
mIU/mL, we found that the latter were related with an
increase in vascular neoformation (p = 0.0001) (Figure 1).
VEGF expression was determined in 57 biopsies due to
insufficient material. Its expression was present in 56% of
the samples. Average percentage of expression was 19 ±
3% (minimum, 0%; maximum, 80%). Intensity was
absent in 44%, mild in 48%, and moderate in 8%. Quali-
tative VEGF expression and expression intensity were not
associated with either VD or hCG serum levels (Table 6).
Median follow-up time was 43 ± 27 months. Recurrence
was observed in 7.5% and death in 11.5% of patients. Dis-
ease-free survival (DFS) at 2 and 5 years was 93.7% (95%
CI, 88–98) and 83% (95% CI, 68–98), respectively. By
analyzing DFS-related factors, only high international risk
correlated with worse prognosis (p  = 0.005). VD and
VEGF expression were not associated with recurrence.
Discussion
hCG is considered an extremely sensitive and specific
marker of germ cell testicular tumors. Its increased serum
levels usually correlate with the existence of viable cancer
cells and it is often associated with disease progression,
recurrence, and a worse prognosis [7,21,22]. Therefore,
hCG levels are part of the international risk factor assess-
ment [23].
In the present study, hCG is associated with elevated VD
in testicular tumors. hCG has been associated with angio-
genesis in normal tissues; this has been confirmed in vivo
and  in vitro by increasing capillary formation and
endothelial cell migration [16,18], and in regulation of
placental angiogenesis [24]. Elevated hCG serum levels
Table 2: Serum tumor markers prior to surgery (101 patients)
Serum tumor markers % Mean ± SD 25% 50%
(min-max)
75% 90% 95% 97.5%
AFP (ng/mL) 1214.3 ± 5892.2 1.85 14.7 (0–53800) 307.5 1748.6 5924.9 14182.0
≤1,000 89.1
1,000–10,000 8.9
≥10,000 2.0
hCG (mIU/mL) 14772 ± 71503 0.0 25.0 (0–479000) 271.0 5000.0 66446.0 352040.0
≤5,000 90.1
5,000–50,000 5.0
≥50,000 5.0
LDH (IU/L) 834 ± 929.1 253.5 475.0 (37–4568) 1070.0 1975.3 3247.2 4156.7
<1.5 × N 31.5
1.5–10 × N 59.8
>10 × N 8.7
SD = standard deviation; AFP = alpha-fetoprotein; hCG = human chorionic gonadotropin; LDH = lactate dehydrogenase
Table 3: Factors associated with vascular density
Variable VD Mean ± SD p
Age (years) 0.434
<26 30.58 ± 25.57
>26 26.02 ± 31.29
AFP (ng/mL) 0.0001
<14.7 17.23 ± 10.39
≥14.7 38.57 ± 36.52
LDH (IU/L) 0.092
<475 23.43 ± 24.61
>475 34.01 ± 34.09
hCG (mIU/mL) 0.0001
<25 18.27 ± 9.04
>25 37.93 ± 37.7
TNM
I 23.84 ± 24.49 0.876 I vs. II
II 22.99 ± 18.49 0.024 I vs. III
III 41.49 ± 40.55 0.036 II vs. III
Metastases (N or M) 0.103
Absent 23.31 ± 24.10
Present 32.88 ± 32.75
SD = standard deviation; AFP = alphafetoprotein; hCG = human 
chorionic gonadotropin; LDH = lactate dehydrogenase; TNM = 
tumor, nodes, metastasis.Journal of Experimental & Clinical Cancer Research 2009, 28:120 http://www.jeccr.com/content/28/1/120
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are present in pregnancy; thus, similarities between tumor
invasion and its vascularization and blastocyst implanta-
tion and placental development have been described
[25,26]. In addition, it has been proposed that hCG could
induce VEGF production in tissues such as placenta [17]
and granulosa cells [18,19]. hCG administration to
women undergoing in vitro fertilization increases urinary
[27], serum, and follicular-fluid VEGF concentrations
[28]. Furthermore, hCG exerts a direct angiogenic effect
on hCG/LH receptor-expressing uterine endothelial cells,
which respond with increased capillary formation in vitro
[16,29]. hCG receptors have been detected in breast carci-
noma tissue, which indicates a probable link to a worse
breast-cancer prognosis during pregnancy, which we pre-
viously hypothesized [30].
We found that predominantly in patients with hCG serum
levels ≥ 25 mIU/mL there was increased tumoral vascular
neoformation, suggesting that hCG could be involved in
angiogenic processes during tumor development. Intrin-
sic hCG activity is clinically relevant when serum concen-
trations are high, for instance, during pregnancy or under
certain pathological conditions that might be associated
to the carcinogenesis of testicular germ cells [6,7].
In this study, a prominent VD (median, 19.0 ± 28.9) was
observed in all tumors, especially non-seminomas, which
would be expected as hCG is elevated in this subtype of
germ tumors. Angiogenesis is essential for malignant neo-
plasm progression and is correlated with poor prognosis
in numerous solid tumors [31], including germ cell testic-
ular cancer [32,33]. Particularly in normal testis, the
endothelial cell proliferation rate is considerably higher
than in other stationary organs. It has been shown that
this rate can be increased via hCG stimulation of Leydig
cells [34]. In addition, a correlation between hCG and
VEGF has been confirmed in rat models and transformed
mouse Leydig cell lines (MA-10 cells) [35,36].
In our results, VEGF expression was limited to 56% of the
tumors studied, showing no clinical or histopathological
association; nevertheless, tissue availability comprised a
factor that could render the data less significant. VEGF
expression in germ cell testicular tumors was previously
found to be significantly higher than in normal testis and
was correlated with microvessel density [11,37]; it was
also described as an indicator of metastatic disease [12].
However, another study reported no prognostic signifi-
cance in relation to metastatic potential, sustaining the
possibility of the existence of additional factors affecting
metastatic capacity. It has also been suggested that there
might be other angiogenic factors, different from VEGF,
which are important in testis tumor biology [37].
No significant association was found between VD and
VEGF expression or prognosis according to disease-free
Table 4: Association of type of germ cell tumor with hCG levels and vascular density
Variable hCG median (mIU/mL) ± SD p Vascular density ± SD p
Seminoma 792.73 ± 2962.1 0.069 20.64 ± 20.14 0.016
Non-seminoma 26954 ± 96511.2 34.56 ± 33.70
hCG = human chorionic gonadotropin; SD = standard deviation
Table 5: Multivariate analysis of factors associated with vascular 
density
Variable Regression co-efficient p
Histology (S vs. NS) 0.2 0.907
Metastatic disease 1.2 0.165
hCG 14 0.04
AFP 13.4 0.08
LDH 0.73 0.92
S = seminoma; NS = non-seminoma; hCG = human chorionic 
gonadotropin; AFP = alpha-fetoprotein; LDH = lactate dehydrogenase
Relationship between tissue vascular density and human cho- rionic gonadotropin (hCG) serum levels Figure 1
Relationship between tissue vascular density and 
human chorionic gonadotropin (hCG) serum levels.Journal of Experimental & Clinical Cancer Research 2009, 28:120 http://www.jeccr.com/content/28/1/120
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survival. This could be a consequence of the low recur-
rence rate in our population (70% of our patients pre-
sented a good international risk), making it difficult to
find a statistical association. With similar results, in a
study of 51 patients with stage I disease, no association
was found between VD and VEGF expression and DFS
[37]. Concerning these results, there is a possibility that
angiogenic factors other than VEGF are relevant in the
development of this neoplasm's vascularization, taking
into account the fact that modulation of the angiopoietin
family has been previously described in non-tumor mod-
els [38,39], as well as fibroblast growth factor [40], metal-
loprotease induction, and cellular adhesion-molecule
expression [41].
Unexpectedly, we found no correlation between hCG
serum levels and VEGF tissue expression. Our results indi-
cate that hCG and VEGF may operate through different
signaling pathways for angiogenesis stimulation, and sug-
gest that hCG is not only an independent prognostic fac-
tor, but that also it additionally plays a role in the
pathophysiology of these neoplasms, representing a
potential therapeutic target in patients showing signifi-
cant elevations of this hormone and who display no
response to treatment.
Conclusion
Our study shows that hCG elevation is independently
associated with high VD in testicular germ cell tumors, but
not with VEGF expression. This suggests that hCG plays an
important function in the angiogenesis and pathophysiol-
ogy of germ cell neoplasms, being a likely target of treat-
ment by receptor inhibition, activity blockage, or
obstruction of intracellular pathways it triggers.
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